STAT3 and kidney cancer: Additionally, it was also found that sunitinib inhibits STAT3 signaling, which is also related to the expansion of the MDSCs; consequently, in patients with kidney cancer treated with sunitinib, a decrease in MDSCs was seen as well as an improved function of T lymphocytes.